Resource Summary Report

Generated by NIF on Jul 29, 2026

Rat Anti-CD45 Monoclonal Antibody, V500 Conjugated, Clone 30-F11

RRID:AB_10697046
Type: Antibody

Proper Citation

BD Biosciences Cat# 561487, RRID:AB_10697046

Antibody Information

URL: http://antibodyregistry.org/AB_10697046

Proper Citation: BD Biosciences Cat# 561487, RRID:AB_10697046

Target Antigen: Rat CD45 V500 Clone 30-F11

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: Rat Anti-CD45 Monoclonal Antibody, V500 Conjugated, Clone 30-F11

Description: This monoclonal targets Rat CD45 V500 Clone 30-F11

Target Organism: mouse

Antibody ID: AB_10697046

Vendor: BD Biosciences

Catalog Number: 561487

Record Creation Time: 20250820T045920+0000

Record Last Update: 20250820T202848+0000

Ratings and Alerts

No rating or validation information has been found for Rat Anti-CD45 Monoclonal Antibody, V500 Conjugated, Clone 30-F11.

No alerts have been found for Rat Anti-CD45 Monoclonal Antibody, V500 Conjugated, Clone 30-F11.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zeng W, et al. (2026) Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy. Cell reports. Medicine, 102528.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Lin H, et al. (2024) Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer cell, 42(12), 2032.

Nagai M, et al. (2024) Sugar and arginine facilitate oral tolerance by ensuring the functionality of tolerogenic immune cell subsets in the intestine. Cell reports, 43(7), 114490.

Charalambous A, et al. (2024) Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas. Molecular cancer therapeutics, 23(11), 1555.

Li G, et al. (2023) Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer cell, 41(2), 304.

Aguiar CF, et al. (2023) Tissue-specific metabolic profile drives iNKT cell function during obesity and liver injury. Cell reports, 42(1), 112035.

Wang X, et al. (2023) Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity, 56(1), 58.

Montgomery AB, et al. (2023) Tissue-resident, extravascular Ly6c- monocytes are critical for inflammation in the synovium. Cell reports, 42(5), 112513.

Deng G, et al. (2022) Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. Journal for immunotherapy of cancer, 10(10).

Liao P, et al. (2022) CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer cell, 40(4), 365.

Sandovici I, et al. (2022) The imprinted Igf2-Igf2r axis is critical for matching placental microvasculature expansion to fetal growth. Developmental cell, 57(1), 63.

Lin H, et al. (2021) Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer cell, 39(4), 480.

Mihi B, et al. (2021) Interleukin-22 signaling attenuates necrotizing enterocolitis by promoting epithelial cell regeneration. Cell reports. Medicine, 2(6), 100320.

Zavareh RB, et al. (2021) HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell chemical biology, 28(2), 158.

Giampazolias E, et al. (2021) Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell, 184(15), 4016.

Haas MS, et al. (2021) mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment. Molecular cancer research : MCR, 19(4), 717.

Cossarizza A, et al. (2021) Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European journal of immunology, 51(12), 2708.

Rao S, et al. (2021) Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell stem cell, 28(5), 833.

Kato D, et al. (2020) GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. eLife, 9.